Caption: The panel voted 18-6 in favor of flibanserin for hypoactive sexual desire
Current strategies for therapists treating hypoactive sexual desire
disorder are primarily based on subjective information," explains Irwin Goldstein, editor-in-chief of The Journal of Sexual Medicine.
Key words: Orgasm Hypoactive sexual desire
disorder Waist-hip ratio Psychoevolution Female sexuality Sexual compatibility Sexual dysfunction
The company's lead product candidate, Lorexys, is currently positioned to advance to a Phase 2b clinical trial for the treatment of hypoactive sexual desire
disorder (HSDD) in women.
At a joint meeting of two Food and Drug Administration advisory panels in June, members of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted 18-6 that the overall benefit-risk profile of flibanserin supported approval for treating hypoactive sexual desire
disorder (HSDD) in premenopausal women, provided that certain risk management options beyond labeling were implemented.
This tells me there is a physiologic means of assessing hypoactive sexual desire
and that as we move forward with therapeutics, whether it's counseling or medications, we can look to see whether changes occur in those regions," he said.
A Food and Drug Administration advisory panel unanimously agreed that concerns about the risks of flibanserin outweighed any evidence that the drug was effective as a treatment for premenopausal women with hypoactive sexual desire
An FDA advisory panel unanimously agreed that concerns about the risks of flibanserin outweighed any evidence that the drug was effective as a treatment for premenopausal women with hypoactive sexual desire
The ten comprehensive articles from international contributors here include clinically essential information in covering new developments in research (including clinical and research evaluations of sexual dysfunctions) and such specific conditions as hypoactive sexual desire
disorder, erectile dysfunction, and premature ejaculation.
Researchers tested the patch on 77 women who suffered early menopause due to the surgery and developed hypoactive sexual desire
ABSTRACT: This study addressed two issues concerning the clinical and theoretical relevance of depression to hypoactive sexual desire
disorder (HSD): (a) whether reliable differences among depressed, mildly depressed, and non-depressed women with HSD could be identified; and (b) whether depression influenced participation in or outcome following orgasm consistency training (OCT).
LibiGel (testosterone gel) is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire
disorder (HSDD) in menopausal women.